Literature DB >> 6474162

Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.

D Pickar, R Labarca, M Linnoila, A Roy, D Hommer, D Everett, S M Paul.   

Abstract

Plasma-free homovanillic acid, a major metabolite of dopamine, was measured in chronically ill schizophrenic patients both before and during treatment with the antipsychotic phenothiazine, fluphenazine. Neuroleptic treatment was associated with a significant time-dependent decrease in plasma homovanillic acid from pretreatment values, which were significantly elevated when compared with those of age- and sex-matched healthy control subjects. Further, both the absolute concentrations as well as the neuroleptic-induced reductions in plasma homovanillic acid determined over 5 weeks of neuroleptic treatment were statistically significantly correlated with ratings of psychosis and improvement in psychosis, respectively. These findings suggest that the delayed effects of neuroleptic agents on presynaptic dopamine activity may more closely parallel their therapeutic actions than do their immediate effects in blocking postsynaptic dopamine receptors and that a decrease in dopamine "turnover" may be responsible for their antipsychotic effects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6474162     DOI: 10.1126/science.6474162

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  26 in total

Review 1.  Clozapine--pharmacokinetic investigations and biochemical effects in man.

Authors:  M Ackenheil
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Effects of antipsychotic medication on electromyographic responses to transcranial magnetic stimulation of the motor cortex in schizophrenia.

Authors:  N J Davey; B K Puri; H S Lewis; S W Lewis; P H Ellaway
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

3.  Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients.

Authors:  J A Den Boer; D P Ravelli; J Huisman; J Ohrvik; W M Verhoeven; H G Westenberg
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.

Authors:  E Suzuki; S Kanba; H Koshikawa; M Nibuya; G Yagi; M Asai
Journal:  J Psychiatry Neurosci       Date:  1996-05       Impact factor: 6.186

5.  Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function.

Authors:  J G Csernansky; S Glick; J Mellentin
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 6.  Clonazepam improves dopamine supersensitivity in a schizophrenia patient: a case report.

Authors:  Mina Fukai; Tetsu Hirosawa; Tetsuya Takahashi; Reizo Kaneda; Mitsuru Kikuchi; Yoshio Minabe
Journal:  Ther Adv Psychopharmacol       Date:  2016-12-02

Review 7.  The ageing brain, neuroleptic drugs and the enigma of schizophrenia.

Authors:  J L Waddington
Journal:  Ir J Med Sci       Date:  1988-05       Impact factor: 1.568

8.  Catatonia: short-term response to lorazepam and dopaminergic metabolism.

Authors:  G Northoff; J Wenke; L Demisch; J Eckert; B Gille; B Pflug
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

9.  GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients.

Authors:  Aurora Arrúe; Ricardo Dávila; Mercedes Zumárraga; Nieves Basterreche; Miguel A González-Torres; Biotza Goienetxea; Maria I Zamalloa; Juan B Anguiano; José Guimón
Journal:  Neurochem Res       Date:  2009-08-22       Impact factor: 3.996

Review 10.  The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness.

Authors:  R Miller
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.